Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

EW - Edwards Lifesciences Corporation Latest News | Finranks

Home

EW

E

Edwards Lifesciences Corporation (EW)

NYQ – Real Time Price. Currency in USD

79.34

-2.76 (-3.36%)

At close: Mar 27, 2026, 4:00 PM EDT

79.61

+0.27 (0.34%)

After-hours: Mar 27, 2026, 6:14 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Edwards Lifesciences: More Appeal For The Heart

Edwards Lifesciences: More Appeal For The Heart

Edwards Lifesciences delivered 11% revenue growth in 2025, driven by robust TAVR and accelerating TMTT businesses. Edwards Lifesciences guides for 8-10% sales growth and adjusted EPS of $2.90-$3.05 in 2026, with TMTT sales expected to rise 40%. Valuation has compressed to 26x forward earnings, supported by a strong net cash position and ongoing share repurchases.

Edwards Lifesciences Stock Up 22.1% in a Year: What's Driving It?

Edwards Lifesciences Stock Up 22.1% in a Year: What's Driving It?

EW shares jump 22.1% in a year as growth in TMTT and strong adoption of PASCAL, EVOQUE and SAPIEN technologies fuel momentum.

Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 Transcript

Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 Transcript

Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 Transcript

Edwards Lifesciences Corporation (EW) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Edwards Lifesciences Corporation (EW) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Edwards Lifesciences Corporation (EW) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside

5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside

ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.

Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Edwards Lifesciences Corporation (EW) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

Edwards Lifesciences Corporation (EW) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

Edwards Lifesciences Corporation (EW) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

Videos

No Data

There is no data to display

Press releases

Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose

Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose

IRVINE, Calif.--(BUSINESS WIRE)--At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural heart disease can live longer, healthier lives. As part of this commitment, Edwards announced the impact and renewed vision for Every Heartbeat Matters, its signature global health initiative, to help 2 million more patients facing barriers worldwide access.

Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Edwards Lifesciences Reports Fourth Quarter Results

Edwards Lifesciences Reports Fourth Quarter Results

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant cu.

Edwards Comments on JenaValve Acquisition

Edwards Comments on JenaValve Acquisition

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company's proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes that the acquisition would have been in the best interest of a large, growing and underserved group of pati.